subscribeSubscribe
Bristol Myers Squibb`s Biologic Orencia (abatacept) Receives Approval in the U.S.

Bristol Myers Squibb`s Biologic Orencia (abatacept) Receives Approval in the U.S.
FDA
30 Oct 2023
Share Share
Coya announces an Agreement with Dr. Reddy’s to License biosimilar Abatacept

Coya announces an Agreement with Dr. Reddy’s to License biosimilar Abatacept
BUSINESSWIRE
21 Mar 2023
Share Share
NIH-led Covid-19 trial shows immune modulator drugs boost survival

NIH-led Covid-19 trial shows immune modulator drugs boost survival
CLINICALTRIALSARENA
18 Jul 2022
Share Share
BMS’ Orencia boosts survival in Phase III Covid-19 trial

BMS’ Orencia boosts survival in Phase III Covid-19 trial
CLINICALTRIALSARENA
03 Jun 2022
Share Share
Immune modulator drugs improves survival for people hospitalised with COVID-19

Immune modulator drugs improves survival for people hospitalised with COVID-19
EXPRESS PHARMA
03 Jun 2022
Share Share
Bristol Myers` Biologic Orencia (Abtacept) Receives Approval in the U.S.

Bristol Myers` Biologic Orencia (Abtacept) Receives Approval in the U.S.
FDA
13 Apr 2022
Share Share
BMS`s Orencia wins FDA nod for prevention of GVHD

BMS`s Orencia wins FDA nod for prevention of GVHD
K. Dunleavy FIERCEPHARMA
16 Dec 2021
Share Share
BMS` Orencia snagged priority review in transplant rejection

BMS` Orencia snagged priority review in transplant rejection
F. Kansteiner FIERCEPHARMA
24 Aug 2021
Share Share
Bristol Myers`s Orencia (Abatacept ) Receives Supplemental Approval in US

Bristol Myers`s Orencia (Abatacept ) Receives Supplemental Approval in US
FDA
24 Jun 2020
Share Share
Abbvie`s Rinvoq matches BMS` Orencia in head-to-head RA trial

Abbvie`s Rinvoq matches BMS` Orencia in head-to-head RA trial
Kyle Blankenship FIERCE PHARMA
08 Jun 2020
Share Share